Form 4: Design Therapeutics Director William Arsani Granted 19,000 Stock Options

Design Therapeutics, Inc. Director William Arsani was granted 19,000 stock options with an exercise price of $4.01, vesting over 12 months starting June 10, 2025.

Summary

• William Arsani, a Director of Design Therapeutics, Inc. (DSGN), was granted 19,000 stock options.
• The options have an exercise price of $4.01 per share.
• The transaction date for the grant was June 10, 2025.
• The options will vest in equal monthly installments over 12 months following June 10, 2025.
• The options will be fully vested by the date of the Company's next annual meeting of stockholders, if earlier than the 12-month period.
• The options expire on June 9, 2035.

Sentiment

Score: 5

Explanation: The document reports a standard, routine compensation event (stock option grant) to a director, which is neutral in sentiment. It does not indicate positive or negative operational or financial performance.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.

Negatives

• No specific negatives are indicated by this standard compensation filing.

Future Outlook

The granted stock options will vest in equal monthly installments over 12 months following June 10, 2025, or fully vest by the date of the Company's next annual meeting of stockholders, whichever is earlier. The options are exercisable until June 9, 2035.

Industry Context

This Form 4 filing details a standard equity compensation grant to a director, a common practice across industries to align management and board interests with shareholder value. Such grants are typical in the biotechnology and pharmaceutical sectors, where long-term incentives are crucial for retaining talent and driving innovation.

Comparison to Industry Standards

• The grant of 19,000 stock options to a director is a common form of equity compensation.
• The vesting schedule (12 months or next annual meeting) is a relatively short vesting period for director options, which often vest over 3-4 years, though shorter periods are not uncommon, especially for annual grants.
• The exercise price of $4.01 is the market price on the grant date, which is standard for incentive stock options.
• Without knowing the director's full compensation package or the company's peer group compensation practices, a direct comparison to specific companies like 'Biogen' or 'Gilead Sciences' is not possible from this document alone, but the mechanism is consistent with industry norms.

Related Party Transactions

• The grant of stock options to William Arsani, a Director of Design Therapeutics, Inc., constitutes a transaction with a related party (company insider).

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases. It also represents potential future dilution if the options are exercised.
• Employees: No direct impact on general employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The stock options granted to William Arsani will begin vesting in equal monthly installments over 12 months starting June 10, 2025.
• The options will fully vest by the date of the Company's next annual meeting of stockholders, if earlier.
• The options will remain exercisable until their expiration date of June 9, 2035.

Key Dates

Keywords

Design Therapeutics, DSGN, Stock Option Grant, Form 4, Insider Transaction, Director Compensation, Equity Compensation, William Arsani